You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A High-Throughput, Multi-Omic Assay of Tumor Biomarkers from Single-Cells

    SBC: ISOPLEXIS CORPORATION            Topic: 172

    SUMMARY Although solid tumors oftentimes arise from the uninhibited growth of a single aberrant cellthe population of cells within a tumor are genetically and molecularly heterogenousThis makes it very difficult to evaluate a therapy s efficacy when using bulk population measurementsFurthermorerecent research has implicated microRNAsmiRNAsas drivers of progression and malignancy in many tumor type ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: NIEHS

    Summary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. A Combined High-Throughput Single-Cell Transcriptomic and Secretomic Assay for Neurodegenerative Disease Biomarker Discovery

    SBC: ISOPLEXIS CORPORATION            Topic: 105

    In this Phase I application IsoPlexis proposes to deliver a novel method for targeted profiling of both the transcriptome and secretome from an array ofsingle central and peripheral immune cellsSpecificallywe will deliver a single cellmRNA and secreted protein capture assay with proven sensitivity for detecting the most important predictive biomarkers for neurodegenerative diseasesThere is growing ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contr ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. IMPROVEMENT TO OZONATING WATER FOR POST-HARVEST WASHING THROUGH NANOBUBBLES

    SBC: En Solucion Inc            Topic: FDA

    AbstractAs consumer demand for fresh produce continues to growso do concerns by the Food and Drug AdministrationFDAabout foodborne illnesses and foodborne disease outbreaksPostharvest wash is a critical control point in fresh produce processing for reducing or eliminating pathogens and other field acquired contaminants that can result in such outbreaksCurrent methods of post harvest washing typica ...

    SBIR Phase I 2018 Department of Health and Human ServicesFood and Drug Administration
  7. Development of an a MC1R selective companion diagnostic imaging probe

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with high affinity and specificityThrough our SBIR Phase I contractwedemonstrated that MC R targetedAc DOTA MTIlacks of overt toxicity at single doses thatproduce significant efficacy against uveal and cutane ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Large Pore SPP Particles for Protein Separations

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    ABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Authentication quantitation and detection of adulteration in botanical dietary supplements using an automated chemometric platform

    SBC: MIDI, INC.            Topic: FDA

    Abstract The objective of this SBIR Phase I proposal is to test the feasibility for development of an automated platform that can perform the followingIdentify botanical components of dietary supplements throughout the supply chain by use of chemicalanalysis and integrated pattern recognition softwareDetect the presence of adulteration by use of HPLCand UHPLCanalysis of bioactive compounds andby u ...

    SBIR Phase I 2018 Department of Health and Human ServicesFood and Drug Administration
US Flag An Official Website of the United States Government